ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress

SAN DIEGO, Calif. ­­– June 8, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that Phase 1/2 clinical data for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate being evaluated for the treatment of hereditary angioedema (HAE), will be presented at the 2026 Annual Meeting of […] The post ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data Supporting the Ongoing Phase 3 STOP-HAE Clinical Trial at the 2026 Annual EAACI Congress appeared